Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$3.0b

Supernus Pharmaceuticals Future Growth

Future criteria checks 4/6

Supernus Pharmaceuticals is forecast to grow earnings and revenue by 58.7% and 15.3% per annum respectively while EPS is expected to grow by 60.8% per annum.

Key information

58.7%

Earnings growth rate

60.83%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate15.3%
Future return on equityn/a
Analyst coverage

Good

Last updated19 Dec 2025

Recent future growth updates

Recent updates

Supernus Pharmaceuticals: Heading In The Right Direction

Sep 17

We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease

Sep 10
We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease

Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price

Jul 23
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price

Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking

Feb 10
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking

Supernus: New Approval Holds Promise Of Increased Growth

Feb 06

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
User avatar

Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics

Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Earnings and Revenue Growth Forecasts

NasdaqGM:SUPN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,0001062522715
12/31/20268671001072016
12/31/2025703-441371886
9/30/2025682-197172N/A
6/30/202566564186187N/A
3/31/202566862163164N/A
12/31/202466274171172N/A
9/30/202465260172173N/A
6/30/20246305154155N/A
3/31/2024597-16100100N/A
12/31/20236081111111N/A
9/30/2023611269394N/A
6/30/2023634437172N/A
3/31/202366852162162N/A
12/31/202266761116117N/A
9/30/202265938138138N/A
6/30/202263057120120N/A
3/31/2022601739495N/A
12/31/202158053125127N/A
9/30/202156482108110N/A
6/30/2021571100117120N/A
3/31/2021556111163166N/A
12/31/2020520127135138N/A
9/30/2020477129145150N/A
6/30/2020424118177182N/A
3/31/2020402116114119N/A
12/31/2019393113142143N/A
9/30/2019408106131132N/A
6/30/2019409105N/A157N/A
3/31/2019404103N/A135N/A
12/31/2018409111N/A129N/A
9/30/201838199N/A132N/A
6/30/201835987N/A109N/A
3/31/201833573N/A128N/A
12/31/201730257N/A115N/A
9/30/201727658N/A103N/A
6/30/2017253104N/A92N/A
3/31/201722897N/A83N/A
12/31/201621591N/A67N/A
9/30/201619684N/A64N/A
6/30/201617926N/A35N/A
3/31/201616318N/A32N/A
12/31/201514714N/A35N/A
9/30/201513511N/A18N/A
6/30/20151185N/A14N/A
3/31/20151125N/A-6N/A
12/31/201493-11N/A-24N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: SUPN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SUPN is expected to become profitable in the next 3 years.

Revenue vs Market: SUPN's revenue (15.3% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: SUPN's revenue (15.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 14:03
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
Pavan PatelBofA Global Research
David BuckB. Riley Securities, Inc.